1. M34 Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the tomorrow and inpulsis trials. (15th November 2017) Authors: Noth, I; Wijsenbeek, M; Kolb, M; Bonella, F; Moros, L; Wachtlin, D; Corte, TJ Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P168 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the united states. (15th November 2016) Authors: Maher, T; Noth, I; Allinger, A; Kaul, M; Conoscenti, CS; Oelberg, D Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S109 Genome-wide analysis of longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis. (11th November 2022) Authors: Allen, RJ; Oldham, JM; Jenkins, DA; Leavy, OC; Guillen-Guio, B; Melbourne, CA; Ma, SF; Jou, J; Kim, JS; Fahy, WA; Oballa, E; Hubbard, RB; Navaratnam, V; Braybrooke, R; Saini, G; Roach, KM; Tobin, MD; Hirani, N; Whyte, MKB; Kaminski, N Journal: Thorax Issue: Volume 77(2022)Supplement 1 Page Start: A67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. T1 Meta-analysis of idiopathic pulmonary fibrosis genome-wide analyses identifies three novel genetic signals associated with disease susceptibility. (12th November 2019) Authors: Allen, RJ; Guillen-Guio, B; Oldham, JM; Ma, SF; Dressen, A; Paynton, ML; Kraven, LM; Obeidat, M; Li, X; Braybrooke, R; Fingerlin, TE; Hall, IP; Sayers, I; Tobin, MD; Maher, TM; Schwartz, DA; Yaspan, BL; Molyneaux, PL; Flores, C; Noth, I Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗